health consulting inc

136-39 41st ave apt 6c
flushing, new york 11355

NYS Entity Status
ACTIVE

NYS Filing Date
AUGUST 18, 2014

NYS DOS ID#
4623175

County
QUEENS

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2014 - HEALTH CONSULTING INC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Restaurant Review: A New Kind of Sichuan Restaurant for New York
    By PETE WELLS - Tuesday Aug 1, 2017

    In downtown Flushing, Queens, Guan Fu Sichuan shows off the rich variety of flavors beyond the familiar blast of chiles.

    Source: NYT > Home Page
  • Letter of Recommendation: Letter of Recommendation: Karaoke at Home
    By JENNY ZHANG - Friday Jul 7, 2017

    Solo singing as an antidote to bullying, racism and rage.

    Source: NYT > Home Page
  • The Look: New York City Parks in the Summer: Romance, Games and a Performance for a Dying Tree
    By DANIEL ARNOLD, JOANNA NIKAS and EVE LYONS - Saturday Sep 2, 2017

    Daniel Arnold spent the last two months photographing parks in all five boroughs. The experience showed him “a very different pulse of the city.”

    Source: NYT > Home Page
  • A New Kind of Classroom: No Grades, No Failing, No Hurry
    By KYLE SPENCER - Friday Aug 11, 2017

    Mastery-based learning allows students to learn at their own pace.

    Source: NYT > Home Page
  • Holiday Sales Forecasts Are Rosy, but Not for All Retailers
    Tuesday Oct 3, 2017

    Sales overall are likely to be strong over the winter holidays, buoyed by low unemployment and rising stock markets that help high-income shoppers feel flush, according to several retail industry groups and consultants.

    Source: The Wall Street Journal: U.S. Business
  • Cancer drug research moving fast in immunotherapy field
    By Michelle Fay Cortez - Tuesday Sep 5, 2017

    The last few weeks have been historic in the fight against cancer. Novartis got approval for the first treatment in a revolutionary new class of drugs, shortly after Gilead Sciences Inc. spent $11.9 billion on a biotech company working in the field. Neither can rest on its laurels. Research in the field is moving so fast that today’s breakthroughs can easily become tomorrow’s has-beens. “I can’t think of any other therapies in oncology that have seen such rapid development,” said Rachel Webster, senior director of oncology at Decision Resources Group, a health care research and consulting firm in London.

    Source: SFGATE.com: Business and Technology News